Volume 2, Issue 9


Antidermatophytic activity of Apamarga-Mulaka Seeds specific to Sidhma (Pityriasis versicolor) in children - A clinical study


Author: Khatri Ravi Shankar1, Singh B.M.1, Tilak Ragini2, Singh Girish3

1. Department of Kaumarbhritya/Bal roga, Faculty of Ayurveda, IMS, BHU.
2. Department of Microbiology, IMS, BHU.
3. Division of Biostatistics Department of community medicine, IMS, BHU.

Abstract: Background: Apamarga (Achyranthes aspera Linn.) and Mulaka (Raphenus sativus Linn.) drugs are being used by Ayurveda to cure the Sidhma (~Pityriasisversicolor) for many centuries in children. Objective: To assess the comparative effect of 10% glycerin preparation-Apamarga and Mulaka Seeds’ dried water extract and-1% clotrimazole lotion in Sidhma (Pityriasis versicolor) disease affected children, aged from 1-16 years irrespective to sex. Material & Method: A total of 40 cases, of both sex of Sidhma (Pityriasis versicolor) were taken and randomly allocated, irrespective to severity of disease, into – a trial group -A (n=20) and another control group-B (n=20) based on the 10% glycerin based trial drug Apamarga-Mulaka Seeds dried water extract and control drug-1% clotrimazole lotion applied over the skin lesion, respectively, for 42 days. Skin lesion characteristics of both groups were observed at first, second, third and fourth follow up. Observation and Results: The analysis of gathered data in respect to types and distribution of rashes, color of rashes, size of rashes, itching and scaling of Pityriasisversicolor lesions in children shows statistically significant (<0.001) effect in trial group when compared to the control group drug on 1st & subsequent follow up. During the study period, no adverse effect was noted. Conclusion:  Early & significant effect of the trial drug suggests its safer and effective use in treatment of Sidhma (Pityriasis versicolor).

Download Full Article: Click Here


Support Us

If you are interested in supporting our work and would like to contribute, you are welcome to mail me at jpbr.anil@gmail.com or at info@thepharmajournal.com it will be a great help and will surely be appreciated.